Lexicon Announces Exclusive Licensing Agreement With Viatris For Sotagliflozin In All Markets Outside The U.S. And Europe
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals has entered into an exclusive licensing agreement with Viatris for the commercialization of Sotagliflozin in all markets outside the U.S. and Europe. Lexicon retains sole commercialization rights in the U.S. and Europe. Sotagliflozin was approved by the FDA in 2023 for reducing cardiovascular risks in adults.
October 16, 2024 | 8:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viatris has secured an exclusive licensing agreement with Lexicon Pharmaceuticals for Sotagliflozin in markets outside the U.S. and Europe, potentially expanding its product portfolio and market reach.
The licensing agreement allows Viatris to commercialize Sotagliflozin in new markets, potentially increasing its revenue and market presence. The FDA approval of the drug adds credibility and potential demand.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80